Royalty-Bearing Products. (a) ORTHO shall pay to CTI a royalty equal to the applicable Royalty Percentage set forth below on all Royalty Bearing Products in the Royalty Bearing Territory.
(b) Royalties shall be equal to the percentage of annual Royalty Bearing Sales set forth below (the "Royalty Percentage"): (The information below marked by ***** has been omitted by a request for confidential treatment. The omitted portion has been separately filed with the Commission.)
Royalty-Bearing Products. Notwithstanding Sections 5.1 through Section 5.4, the royalties upon Platelet Products, Plasma Products, RBC Products and Residual Products shall be applicable to such Products solely to the extent that they are Royalty-Bearing Products.
Royalty-Bearing Products. Except with respect to Co-Developed Products, Combination Products, Option Products and Converted Products, Incyte shall pay to Agenus royalties on Net Sales of each Royalty-Bearing Product, on a Royalty-Bearing Product-by-Royalty-Bearing Product basis, in each Calendar Year as follows: The portion less than or equal to [**] 6% The portion greater than [**] and less than or equal to [**] [**] The portion greater than [**] and less than or equal to [**] [**] The portion greater than [**] 12%
Royalty-Bearing Products. Subject to Section 7.1(b)(i), BMS shall be solely responsible for creating all packaging and promotional materials for the Royalty-Bearing Products. BMS shall own all right, title and interest in and to any and all such promotional materials, including all applicable copyrights, trademarks (other than Exelixis’ name and logo), program names and domain names.
Royalty-Bearing Products. Amgen shall pay Infinity the following amounts within [**] days after the first achievement by Amgen, its Affiliates or its sublicensees of the corresponding milestone events with respect to each Royalty-Bearing Product. Each payment under this Section 4.3.1 shall be made only once per Amgen Target, for the first Royalty-Bearing Product Developed against such Amgen Target for which such milestone event is achieved and only once per Royalty-Bearing Product regardless of the number of times a milestone event is achieved for the same Royalty-Bearing Product. The Parties recognize that a single Royalty-Bearing Product may modulate more than one Amgen Target. For the avoidance of doubt, in the event that a single Royalty-Bearing Product modulates more than one Amgen Target, (1) each payment under this Section 4.3.1 shall still be made only once with respect to such Royalty-Bearing Product,
Royalty-Bearing Products. (a) If either Party has exercised its Opt-Out Right with respect to a Co-Development Target during the Phase I Completion Opt-Out Period for the most advanced RNAi Therapeutic Product directed to such Target, and the other Party is the Continuing Party with respect to such Target and Royalty-Bearing Products directed thereto, then the Continuing Party shall make a non-refundable, non-creditable milestone payment to the Opt-Out Party in the amount of $[**] no later than [**] business days after the earliest date on which the first NDA Filing for the first such Royalty-Bearing Product has been achieved.
(b) If either Party has exercised its Opt-Out Right with respect to a Co-Development Target during the Phase II Completion Opt-Out Period for the most advanced RNAi Therapeutic Product directed to such Target, and the other Party is the Continuing Party with respect to such Target and Royalty-Bearing Products directed thereto, then the Continuing Party shall make the non-refundable, non-creditable milestone payments to the Opt-Out Party set forth below no later than [**] business days after the earliest date on which the corresponding milestone event has been achieved for the first time with respect to the first such Royalty-Bearing Product. MILESTONE EVENT PAYMENT --------------- ------- Initiation of Phase III Study $[**] First NDA Filing $[**]
Royalty-Bearing Products. Neurocrine will be solely responsible for all costs and expenses relating to the Commercialization of all Royalty-Bearing Products.
Royalty-Bearing Products. Buyer and Seller hereby agree that the term "Royalty Bearing Products" as defined in Section 1.18 of the previous Semiconductor Cross License between Buyer and Seller having an effective date of January 1, 1994 (the "Previous Cross-License"), the term of which and the respective licenses granted under which expire December 31, 1998, shall not include any product manufactured at any facility transferred by Seller to Buyer pursuant to this Agreement, and that the term "Net Sales Billed" as defined in Section 1.20 of the Previous Cross-License shall not include any revenues of any kind derived as a result of Buyer's operation of the Business or any of the Acquired Assets.
Royalty-Bearing Products. Subject to the terms and conditions of this Agreement, in relation to each Royalty-Bearing Product, the Opt-Out Party hereby grants the Continuing Party a license under ALNYLAM Technology or MERCK Technology, as the case may be, to Develop, Manufacture and Commercialize such Royalty-Bearing Product in the Field in the Territory. Such license shall be exclusive and royalty-bearing for the royalty term of such Royalty-Bearing Product as set forth in Section 8.3.3 in each country in the Territory, and shall thereafter be a non-exclusive, royalty-free license to Develop, Manufacture and Commercialize such Royalty-Bearing Product in the Field in such country. Such licenses shall include the right to grant sublicenses and licenses as provided in Section 7.2 below.
Royalty-Bearing Products. Subject to the terms of Section 7.2.5, the Continuing Party shall be entitled to grant sublicenses of its rights under this Agreement (and licenses under any Joint Collaboration IP) with respect to Royalty-Bearing Products to Third Parties to Develop and Commercialize such Royalty-Bearing Products. The Continuing Party shall notify the Opt-Out Party following the grant of any such sublicense or license, as the case may be.
